Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
Date:6/9/2009

ts in glucose tolerance and insulin sensitivity
  • Significant reduction in plasma glucose levels in extremely hyperglycemic animals
  • No harmful effects such as low blood glucose levels (hypoglycemia) or detrimental changes in kidney function with 3-6 month exposure in normal or diabetic animals.

  • "Our preclinical research during the past year on ISIS-SGLT2Rx extends previous findings and demonstrates potent and sustained reduction of blood glucose levels with good safety and tolerability in multiple animal models including non-human primates. Collectively, the data suggest that ISIS-SGLT2Rx could result in sustained and significant reductions in blood glucose levels in diabetic patients and could be used as an infrequent injectable drug to help control blood sugar. This year, we have initiated our first clinical trial on ISIS-SGLT2Rx that will not only assess the safety of the drug in healthy volunteers, but may also provide us with information on the activity of the drug by measuring the effect of ISIS-SGLT2Rx on glucose excretion in urine. We are excited to continue to move this drug forward through development," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Disorders and Head of Translational Medicine at Isis Pharmaceuticals.

    Isis scientists presented new data demonstrating that antisense reduction of retinal binding protein 4 (RBP4) caused significant improvements in insulin sensitivity with associated improvement in cardiac glucose metabolism. These data suggest that RBP4 could be an important new therapeutic target for type 2 diabetes and associated cardiac disease.

    In addition to new data demonstrating the ability of antisense drugs to significantly improve insulin sensitivity in diabetic animals, Isis also presented data from its obesity drug discovery program. In an oral presentation, Isis reported that antisense reduct
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
    2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
    3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
    4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
    6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
    7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
    8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
    9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
    10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
    11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... LONDON , July 23, 2014  Lightlake ... developing addiction treatments based on its expertise in ... an investigational new drug application ("IND") with respect ... Lightlake also announced today that it has received ... Drug Abuse ("NIDA"), part of the National Institutes ...
    (Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
    (Date:7/23/2014)... , July 23, 2014  ACON Equity Partners III, ... Investments, L.L.C. ("ACON") announced it has completed the purchase ... from Audax Group and Parthenon Capital Partners. IWP is ... billion Workers, Compensation, Automobile Personal Injury Protection and Personal ... . As part of this ...
    Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3ACON Investments Acquires Injured Workers Pharmacy 2ACON Investments Acquires Injured Workers Pharmacy 3
    ... Therapeutics, Inc. (Nasdaq: ECTE ), a company ... wireless, transdermal continuous glucose monitoring system and its Prelude® ... results for the year ended December 31, 2011.  Echo,s ... website at www.echotx.com . 2011 ...
    ...   Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... of senior vice president and chief commercial officer. Mr. Palekar ... activities. "Rohan has an outstanding track record of ... president and CEO of Avanir. "I am delighted that we ...
    Cached Medicine Technology:Echo Therapeutics, Inc. Announces 2011 Financial Results 2Echo Therapeutics, Inc. Announces 2011 Financial Results 3Echo Therapeutics, Inc. Announces 2011 Financial Results 4Echo Therapeutics, Inc. Announces 2011 Financial Results 5Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 2Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer 3
    (Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
    (Date:7/23/2014)... 23, 2014 (HealthDay News) --,Jealousy may not be the ... can get downright possessive when it comes to the ... affection toward what was actually a stuffed dog, the ... pushing the stuffed dog aside, report researchers from the ... streak only surfaced when owners were attending to the ...
    (Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
    (Date:7/23/2014)... County, NJ (PRWEB) July 23, 2014 ... is the first hospital in New Jersey to receive ... most advanced robotics platform in the da Vinci series. ... and a profound step forward in innovation. The intuitive ... used across a wide spectrum of minimally invasive and ...
    (Date:7/23/2014)... Vancouver, BC (PRWEB) July 23, 2014 ... has recently announced the launch of its custom orthotics ... correcting and eliminating foot abnormalities in order to restore ... the joints and cause less fatigue and pain. In ... and reduced pressure in the foot, resulting in relief ...
    Breaking Medicine News(10 mins):Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2
    ... risk of obesity later in life, research suggests , ... during pregnancy reduces an infant,s birth weight, which may ... researchers say. , In a new study, 84 first-time ... groups, with those in the exercise group participating in ...
    ... ... Laboratory Notebook) to be fully supported on the revolutionary Apple iPad. , ... (PRWEB) April 5, 2010 -- Amphora Research ... supported on the revolutionary Apple iPad., , ,"Science often happens in places where using a ...
    ... ... today. This newly launched initiative from MedPage Today, the online daily breaking medical news ... and critical thinkers while preserving their editorial independence. , ... Little Falls, New Jersey (PRWEB) April 5, 2010 ...
    ... finds relationships often founder after failed pregnancy, , MONDAY, April ... when she miscarried at 14 weeks. That she was already ... understand was that having my other children and realizing how ... who lives in Highland Ranch, Colo. , At first, her ...
    ... ... Day on April 7th, Swanson Health Products will donate five percent of the day,s sales ... ... Health Products plans to donate five percent of sales from Wednesday, April 7th, to Vitamin ...
    ... ... Expanded Its Free Webinars to Cover New Obama Health Reform ... Insurance Reimbursement Checks Directly with Valid Assignment and Nondiscrimination Protections ... and Individual Health Plan to Accept Patient Assignment to Send ...
    Cached Medicine News:Health News:Expectant Mom's Exercise Keeps Newborn's Birth Weight Down 2Health News:Amphora's PatentSafe Electronic Laboratory Notebook Fully Supported on the Apple iPad 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 2Health News:MedPage Today Launches New Related SitesTM Initiative with KevinMD.com as First Collaborator 3Health News:For Many Couples, Toll of Miscarriage Lingers 2Health News:For Many Couples, Toll of Miscarriage Lingers 3Health News:For Many Couples, Toll of Miscarriage Lingers 4Health News:Swanson Health Products to Make Donation for Haiti Relief Efforts 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 2Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 3Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 4Health News:Health Reform for Out-Of-Network Providers: Receiving Insurance Checks Directly? - Free Webinars on Why and How 5
    VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
    VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
    VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
    VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
    Medicine Products: